Document:

EX-10.1

 Exhibit 10.1 

FIRST AMENDMENT TO 

SHARE PURCHASE AGREEMENT 

THIS FIRST AMENDMENT TO SHARE PURCHASE AGREEMENT (this “First Amendment”) is entered into and made effective as
of February 1, 2021 (the “Effective Date”), by and between Ocumension Therapeutics, incorporated in the Cayman Islands with limited liability (“Investor”), and EyePoint Pharmaceuticals, Inc., a
Delaware corporation (the “Company”). Investor and the Company are sometimes individually referred to herein as a “Party” or collectively referred to herein as the
“Parties.” 
 RECITALS 

A.    The Parties previously entered into that certain Share Purchase Agreement, dated
December 31, 2020 (the “Purchase Agreement”); 

B.    Section 11.2 of the Purchase Agreement provides that any amendment to the
Purchase Agreement must be in writing and duly executed by authorized representatives of both parties; and 

C.    The Parties desire to amend the Purchase Agreement pursuant to the terms and
conditions of this First Amendment to clarify the Parties intent with respect to the participation rights granted to the Investor in the Purchase Agreement. 

AGREEMENT 
 NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants and conditions set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as
follows: 
 1.    AMENDMENT TO SECTION 6.3. Section 6.3 of the Purchase
Agreement is hereby deleted in its entirety and replaced with the following: 
 “6.3    Purchase
Rights. For so long as Investor owns a number of Shares equal to at least 75% of the Shares it purchases on the Closing Date (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification
effected after the date hereof), if the Company proposes to offer or sell any New Securities (a “Subsequent Financing”), the Company shall offer such New Securities to Investor as follows: 

(a)     The Company shall give notice (the “Offer Notice”) to Investor (y) in
the case of a private placement of New Securities, no later than five Business Days prior to the date of a definitive agreement related thereto and (z) in the case of a Registered offering of New Securities, on the date of the final prospectus
related thereto, in each case, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New
Securities; provided, however, that in the event of a 

  
 1 

 
private placement, the Offer Notice shall include such information regarding the number of New Securities to be offered and the price and terms of such offering that is known to the Company at
such time of delivery of the Offer Notice, with such additional information to be provided promptly after such additional information becomes available to the Company. 

(b)    By notification to and received by the Company within five (5) Business Days after the date the
Offer Notice is given (the “Notice Termination Time”), Investor may elect to purchase or otherwise acquire in a separate Private Placement (as defined below), at the price and on the terms specified in the Offer Notice, up to
such number of New Securities which equals the proportion that the Common Stock then held by Investor bears to the total Common Stock of the Company then outstanding, assuming the sale of New Securities in the Subsequent Financing and full
conversion and/or exercise, as applicable, of all Derivative Securities then outstanding. If the Company receives no such notice from Investor as of such Notice Termination Time, Investor shall be deemed to have notified the Company that it does not
elect to participate in such Private Placement. Any offer made pursuant to Section 6.3(a) or sale pursuant to this Section 6.3(b) shall be made without registration under the Securities Act
pursuant to the exemption provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder as a transaction not involving a public offering (“Private Placement”). The closing of any sale pursuant to
this Section 6.3(b) shall be subject to the closing of the Subsequent Financing and must occur within the later of 90 days of (i) the date that the Offer Notice is given and (ii) the date of the initial sale of New
Securities pursuant to Section 6.3(c). 
 (c)     In the event of any sale of New Securities
to the Investor pursuant to this Section 6.3, the Company shall grant registration rights to Investor with respect to such New Securities on terms no less favorable than those set forth in Appendix 1. 

(d)    The rights in this Section 6.3 shall not be applicable to: 

(i)    shares of Common Stock or Derivative Securities issued in connection with any merger, acquisition,
or business combination; 
 (ii)    shares of Common Stock or Derivative Securities issued in connection
with any commercial transaction approved by the Board of Directors of the Company; 
 (iii)    shares of
Common Stock or Derivative Securities issued as a dividend, stock split, reverse stock split, split-up or other distribution on shares of Common Stock; 

(iv)    shares of Common Stock or Derivative Securities issued to employees or directors of, or consultants
or advisors or contractors to, the Company or any of its Subsidiaries pursuant to a plan, agreement or arrangement approved by the Company’s Board of Directors or the compensation committee of the Board of Directors, including inducement awards
issued pursuant to applicable Nasdaq rules; 

  
 2 

 (v)    shares of Common Stock or Derivative Securities
actually issued upon the exercise, conversion, exchange or settlement of Derivative Securities, provided such issuance is pursuant to the terms of such Derivative Security; 

(vi)    shares of Common Stock or Derivative Securities issued to banks, equipment lessors or other
financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board of Directors of the Company; 

(vii)    shares of Common Stock issued pursuant to at-the-market or equity line of credit programs, including pursuant to that certain Controlled Equity OfferingSM Sales Agreement, dated August 5,
2020, by and between the Company and Cantor Fitzgerald & Co., as may be amended from time to time; and 

(viii)    shares of Common Stock issued pursuant to an employee stock purchase plan, including the
Company’s 2019 Employee Stock Purchase Plan, as may be amended from time to time. 
 (e)     The
rights and obligations set forth in this Section 6.3 shall automatically terminate and be of no further force and effect immediately upon Investor owning a number of Shares equal to less 75% of the Shares it purchases on the Closing
Date (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof).” 

2.    APPLICABLE LAW. This First Amendment shall be governed by, and construed
in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. 

3.    HEADINGS. The bold-faced headings contained in this First Amendment are
for convenience of reference only, shall not be deemed to be a part of this First Amendment and shall not be referred to in connection with the construction or interpretation of this First Amendment. 

4.    SUCCESSORS AND ASSIGNS. This First Amendment shall be binding upon and
inure to the benefit of the parties hereto and their respective successors and permitted assigns. 

5.    CONSTRUCTION. Unless otherwise defined herein, capitalized terms shall
have the meanings set forth in the Purchase Agreement. The terms of this First Amendment amend and modify the Purchase Agreement as if fully set forth in the Purchase Agreement. Upon the effectiveness of this First Amendment, all references in
the Purchase Agreement to “the Agreement” or “this Agreement,” as applicable, shall refer to the Purchase Agreement, as modified by this First Amendment. If there is any conflict between the terms, conditions and obligations of
this First Amendment and the Purchase Agreement, this First Amendment’s terms, conditions and obligations shall control. All other provisions of the Purchase Agreement not specifically modified by this First Amendment are expressly
preserved. This First Amendment may be executed in multiple counterparts and transmitted by facsimile, by electronic mail in portable document format (“PDF”) form or by any other electronic means intended to preserve the
original graphic and pictorial appearance of a Party’s signature, with each such counterpart, facsimile or PDF signature constituting an original and all of which together constituting one and the same original. 

  
 3 

 6.    AUTHORITY. By their
execution of this First Amendment, the undersigned Parties hereby confirm that they are duly authorized to execute this First Amendment and any necessary requisite approval has been obtained with respect to this First Amendment and all matters set
forth herein. 

  
 4 

 IN WITNESS WHEREOF, the Parties have executed this First Amendment as of the
Effective Date. 
  

			
	EYEPOINT PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Nancy Lurker

	Name:	 	Nancy Lurker
	Title:	 	President & CEO
	
	OCUMENSION THERAPEUTICS
		
	By:	 	 /s/ Ye Liu

	Name:	 	Ye Liu
	Title:	 	CEO

 [Signature Page to First Amendment to Share Purchase Agreement]ex_223454.htm

 

Exhibit 10.2

 

 

This Agreement for Professional Services (the “Agreement”), effective January 4, 2021, is by and between Vado Corp., located at 81 Prospect Street Brooklyn, NY 11201 (hereinafter “Vado Corp.” or “Client ”), and Accelerated Online Inc, located at 70 Washington St., Suite 6K Brooklyn, NY 11201 (hereinafter “Accelerated Online” or “Company”).

 

	
			I.

				
			Scope of Work: Accelerated Online will provide corporate and executive management consulting services to Client.

			

 

	
			II.

				
			Payment Terms: The Company shall be paid $7,500 monthly upon execution of this Agreement until the Agreement is terminated. Payments are due upon receipt of any invoice. The Client will reimburse the Company for any extraordinary out-of-pocket expenses that have been approved in advance by the Client.

			

 

	
			III.

				
			Additional Fees: At any time Client may request services and/or projects that are not covered by the Scope of Work ("Additional Services"). Additional consulting services are available to Client and will be scoped and priced on a case-by-case basis.

			

 

	
			IV.

				
			Late Fees: An interest charge of 1.5% per month will accrue on invoices 30 days past due.

			

 

	
			V.

				
			Independent Contractor Assignment: The parties agree that Accelerated Online is an independent contractor. Neither party may assign this agreement without the express written consent of the other party.

			

 

	
			VI.

				
			Intellectual Property Ownership: The results of any work provided under this Agreement and any deliverables under this Agreement conceived or reduced to practice by Company in the course of performing consulting services hereunder (the “Intellectual Property”), shall be the sole and exclusive property of Client and shall be a “work for hire” under the copyright laws of the United States.

			

 

	
			VII.

				
			Termination: This Agreement shall be subject to termination without cause upon thirty (30) days written notice to the other party, by email or overnight mail to the addresses listed above

			

 

	
			VIII.

				
			Indemnification: Because of Client's intimate familiarity with Client's business, Accelerated Online cannot undertake to verify all the facts supplied to Accelerated Online by Client. Because of this, Client agrees to indemnify, defend and hold harmless Accelerated Online and our employees, officers, directors, shareholders, licensees and agents from and against all liabilities, losses, damages or expenses, including reasonable attorneys’ fees and costs, which we or such other person may incur as the result of any brought or threatened claim, suit or proceeding arising from, related to or in connection with the use of any facts or information supplied to Accelerated Online by Client (a “Claim”), including, without limitation, any Claim for (a) infringement or violation of copyright, patent, trademark, or license, or (b) defamation arising out of the nature or use of Client products or services or any assertions we may make on Client's behalf, including assertions about Client, Client products or services, or about Client competitors and any of their products or services, in any materials we may prepare for Client, if the assertions are based on information, representations, reports, data or releases supplied to Accelerated Online by or through Client, or, to the extent different from the foregoing, for which Client is required or undertake to obtain releases or consents, or otherwise which Client approves (“Client Material”) (excluding claims covered under our indemnity below).

			

 

Accelerated Online shall indemnify, defend and hold harmless, Client and its affiliates, and its respective directors, officers, employees and agents from and against any and all claims, demands, suits, actions, judgments, cost and liabilities (including reasonable attorney’s fees) each an “indemnified loss” that arises out of, results from, or is incidental to this Agreement or the work or services performed by Accelerated Online under this Agreement, to the extent such indemnified loss is caused by or results from our negligence or fault of our employees, agents and/or subcontractors.

 

 

 

 

 

 

Accelerated Online’s total aggregate liability for any claim of any kind arising as a result of or related to this Agreement, whether based in contract, warranty, or any other legal or equitable grounds, shall be limited to the amounts received by Accelerated Online from Client for the particular project(s) which form(s) the basis of such claim.

 

EXCEPT FOR LIABILITY ARISING UNDER THIS SECTION, IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT.

 

	
			IX.

				
			Entire Agreement: This agreement sets forth the entire agreement and understanding of the parties with respect to the subject matter set forth herein and thereby supersedes all prior agreements, arrangements and understandings relating to the subject matter. This agreement may be amended only by a written instrument executed by the parties hereto.

			

 

	
			X.

				
			Amendment and Waiver: This agreement may not be amended except by written agreement of the parties.

			

 

	
			XI.

				
			Governing Law: This agreement has been made in the State of New York.

			

 

 

	Vado Corp.	 	 
	 	 	 
	/s/ David Lelong   	 	January 4, 2021
	
			By: David Lelong           

			Title: CEO

			Email: david@vadocorphq.com

				 	Date
	 	 	 
	 	 	 
	Accelerated Online	 	 
	 	 	 
	/s/ David Lelong   	 	January 4, 2021
	
			By: David Lelong        

			Title: CEO

			Email: david@acceleratedonline.net

				 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]